HBIO
HARVARD BIOSCIENCE INC
Next earnings Aug 10, 2026 · consensus $-0.43 EPS, $21.9M rev
Last earnings -20.9% on 2026-05-12
$6.04
▲ +1.34%$6.04▲ +17.58%
over 1Y
L $3.79EODHDH $7.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W-0.2%
1M+4.5%
3M+24.0%
YTD-7.3%
1Y+17.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue declined -8.1% YoY.
Revenue (FY2025) $86.5M · FY2025
HARVARD BIOSCIENCE INC shows $86.5M in FY2025 revenue (-8.1% YoY), a -65.5% net margin, and -412.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $119M | $113M | $112M | $94.1M | $86.5M |
| Gross profit | $67.7M | $60.8M | $66.1M | $54.8M | $49.9M |
| Operating income | $2.07M | -$6.93M | $1.89M | -$6.21M | -$48.6M |
| Net income | -$288K | -$9.52M | -$3.42M | -$12.4M | -$56.7M |
| Diluted EPS | — | -$0.23 | -$0.08 | -$0.28 | -$1.28 |
| Net margin | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$297M
EV / EBITDA—
EV / Sales3.4
EV / FCF54.4
P / FCF49.4
PEG (trailing)—
Earnings yield-21.0%
FCF yield2.0%
Quality & risk
ROIC (est.)-77.4%
Free cash flow$5.47M
Total debt$35.9M
Net cash-$27.3M
Altman Z-Score-1.84 distress
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-092026-06-12open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗S-8Filing2026-06-10open ↗8-KPeriod ending 2026-06-022026-06-02open ↗SDFiling2026-05-27open ↗SCHEDULE 13G/AFiling2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗
Frequently asked
- Is HARVARD BIOSCIENCE INC (HBIO) a buy?
- HBIO currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue declined -8.1% YoY.
- What is HARVARD BIOSCIENCE INC's quality score?
- HBIO scores 39.27450980392156/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001123494, latest 10-Q filed 2026-05-12) · EODHD · as of 6/25/2026, 6:09:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.